CD274 and non-small cell lung carcinoma: Up to 40% of M-NSCLC patients have substantially different anti-PD-1 resistance scores in different regions of the same tumor, which often leads to discordant predictions of the extent of response to anti-PD-1 or anti-PD-L1 inhibitors (41, 70).